Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca sees Crestor benefit

AstraZeneca sees Crestor benefit

31st March 2008

AstraZeneca has confirmed that it is stopping the Crestor Jupiter study early due to unequivocal evidence of the drug being of benefit to patients.

Following advice from the Jupiter steering committee and the Independent Data Monitoring Board, a decision has been taken to stop the study.

There was unequivocal evidence of a reduction in cardiovascular morbidity and mortality among patients who received crestor as compared to those that were given a placebo, the research found.

The latest test was designed to see if treating patients with no evidence of pre-existing cardiovascular disease and low to normal low-density lipoprotein cholesterol but elevated C-reactive protein with 20mg of Crestor once a day would reduce major cardiovascular concerns.

Initial results indicated there is a benefits. The Jupiter study team is now in the process of closing the trial and is scheduling final meetings with more than 15,000 trial participants.

Earlier this month, AstraZeneca released its 2007 annual report.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.